---
schema_version: "secwatch.filing_event.v1"
accession: "0000010795-23-000038"
form_type: "8-K"
ticker: "BDX"
cik: "0000010795"
company_name: "BECTON DICKINSON & CO"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T19:47:53.425743+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# BD Q2 fiscal 2023 revenue $4.82B, adjusted EPS $2.86; raises guidance

## Summary
- Revenue $4.821B, up 1.5% reported (+4.1% currency-neutral); base revenue (ex-COVID) up 6.0% reported (+8.7% currency-neutral).
- GAAP diluted EPS $1.53; adjusted diluted EPS $2.86, up 2.9% reported (+11.2% currency-neutral).
- Company raises full-year base revenue and adjusted EPS guidance midpoints, enabling additional growth investments.
- FDA approval for BD Onclarity HPV assay with SurePath and ThinPrep; BD Vaginal Panel cleared for BD COR system; BD Prevue II system launched.

## SEC filing metadata
- accession: 0000010795-23-000038
- form_type: 8-K
- ticker: BDX
- cik: 0000010795
- company_name: BECTON DICKINSON & CO
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10795/000001079523000038/0000010795-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10795/000001079523000038/bdx-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000010795-23-000038
- JSON: https://secwatch.observer/filing/0000010795-23-000038.json
- Plain text: https://secwatch.observer/filing/0000010795-23-000038.txt

## Key facts
- Earnings Releases
  BECTON DICKINSON & CO reported second quarter of fiscal 2023 results: revenue $4.8 billion, EPS $1.53. Guidance raised.
  - Period: second quarter of fiscal 2023
  - Revenue: $4.8 billion
  - EPS: $1.53
  - Guidance: raised
  - Result: reported results
  source text: BD Reports Second Quarter Fiscal 2023 Financial Results BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges • Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis • Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral • GAAP and adjusted diluted EPS from continuing operations of $1.53 and $2.86, respectively • Company raises full-year base revenue guidance, enabling additional investments in growth and innovation while absorbing lower COVID-only diagnostic testing revenue and incremental FX impacts
  evidence_url: https://www.sec.gov/Archives/edgar/data/10795/000001079523000038/0000010795-23-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.